Ischemic Stroke Biomarker Panels for Small-Lesion Severity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for ischemic stroke, particularly for mild symptoms, suffer from low sensitivity and specificity, with CT scans often yielding false negatives and inadequate detection of small lesions, necessitating improved biomarkers for accurate diagnosis and severity assessment.
Innovation Solution
Development of a biomarker system comprising protein, small molecule, and lipid metabolite markers, including specific markers such as ACOX3, CAP1, and various metabolites, to enhance diagnostic accuracy through machine learning algorithms like Random Forest classification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CT scans are used for diagnosis, then rapid and straightforward exclusion of cerebral hemorrhage is achieved, but detection sensitivity for small lesions less than 1 cm is insufficient
Solution Approach 1:
The patent changes the detection parameter from anatomical imaging (CT/MRI) to molecular biomarker detection in blood samples. This parameter shift enables detection of ischemic stroke at the molecular level, achieving high sensitivity for small lesions while using simple, routine blood testing procedures rather than complex imaging equipment.
Solution Approach 2:
The patent replaces the mechanical/imaging-based diagnostic system (CT scanners, MRI machines) with a biochemical detection system that measures protein and metabolite concentrations in blood. This substitution maintains diagnostic capability while eliminating the need for expensive, complex imaging equipment.
2Measurement precision
If multiple diagnostic markers are used, then diagnostic accuracy is improved, but operational complexity and cost increase
Solution Approach 1:
The patent combines multiple diagnostic markers (proteins and metabolites) into a single integrated diagnostic approach. By measuring a panel of biomarkers together in one blood test, the system achieves high diagnostic accuracy while maintaining operational simplicity, as all markers are assessed simultaneously from a single sample rather than requiring separate tests for each marker.
Solution Approach 2:
The patent develops a universal diagnostic system that uses a single blood sample to assess multiple biomarkers for different aspects of ischemic stroke (diagnosis, severity assessment, prognosis). This multi-functional approach eliminates the need for separate diagnostic procedures for each clinical question, reducing operational complexity while maintaining comprehensive diagnostic accuracy.
Data Source
AI summary
The present invention discloses biomarkers for the severity of ischemic stroke, belonging to the field of biomedicine. The first aspect of the invention provides biomarkers for the severity of ischemic stroke, including protein markers, small molecule metabolite markers, and lipid metabolite markers. The second aspect of the invention provides the use of these biomarkers. The innovation of the biomarkers lies in their ability to provide more accurate diagnostic results, thereby assisting clinicians in better treatment planning. Additionally, these biomarkers offer advantages such as ease of operation and low cost, making them potentially widely applicable in clinical settings.